logo

CCCC

C4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.55 / 10
Outperform

The fundamental score of 6.5/10 indicates favorable quality, driven by strong PB-ROE, Asset-MV, and Gross profit margin factors. However, sub-par Current and Fixed assets turnover ratios temper the outlook. Overall, the company's health is positive but not outstanding.

Fundamental(6.55)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.95
Score1/3
Weight8.23%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight7.23%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.53%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight12.32%
1M Return7.79%
PB-ROE
Value-0.46
Score3/3
Weight19.34%
1M Return11.47%
Current assets turnover ratio
Value0.11
Score0/3
Weight-2.25%
1M Return-1.88%
Fixed assets turnover ratio
Value0.45
Score1/3
Weight-1.95%
1M Return-1.64%
Asset-MV
Value-0.50
Score3/3
Weight28.59%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight12.33%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.36%
1M Return-0.30%
Is CCCC fundamentally strong?
  • CCCC scores 6.55/10 on fundamentals and holds a Discounted valuation at present. Backed by its -45.63% ROE, -395.51% net margin, -1.58 P/E ratio, 1.14 P/B ratio, and 2.34% earnings growth, these metrics solidify its Outperform investment rating.